局部晚期-话题@MedSci

#局部晚期#

176篇内容 | 3365人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1650782, encodeId=4a831650e8282, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Ann Surg：联合血管切除术治疗局部晚期肝门部胆管癌, objectType=article, longId=201376, objectId=5d342013e64b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d342013e64b, replyNumber=0, likeNumber=67, createdTime=2021-03-24, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d342013e64b, moduleTitle=Ann Surg：联合血管切除术治疗局部晚期肝门部胆管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d342013e64b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650786, encodeId=a12d1650e8658, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=ASCO GI 2021：帕博利珠单抗+放化疗全程新辅助治疗局部晚期直肠癌，未能改善NAR评分（NRG-GI002研究）, objectType=article, longId=205931, objectId=2ebe20593162, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ebe20593162, replyNumber=0, likeNumber=80, createdTime=2021-05-29, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ebe20593162, moduleTitle=ASCO GI 2021：帕博利珠单抗+放化疗全程新辅助治疗局部晚期直肠癌，未能改善NAR评分（NRG-GI002研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ebe20593162)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650802, encodeId=f9531650802a7, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！, objectType=article, longId=211335, objectId=282e211335e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=282e211335e4, replyNumber=0, likeNumber=70, createdTime=2021-07-16, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=282e211335e4, moduleTitle=Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=282e211335e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650796, encodeId=f44e1650e96ec, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Lancet Oncol：中山大学肿瘤医院郭翔教授团队通过3期试验证实第三代铂类药物洛铂可有效治疗局部晚期鼻咽癌！, objectType=article, longId=210300, objectId=c2092103002f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2092103002f, replyNumber=0, likeNumber=69, createdTime=2021-10-17, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2092103002f, moduleTitle=Lancet Oncol：中山大学肿瘤医院郭翔教授团队通过3期试验证实第三代铂类药物洛铂可有效治疗局部晚期鼻咽癌！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2092103002f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650774, encodeId=1bf61650e74f7, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Int J Clin Oncol：卡铂或西妥昔单抗加放疗对不能接受顺铂治疗的局部晚期头颈部癌症患者的安全性和有效性, objectType=article, longId=196267, objectId=c95e19626e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c95e19626e25, replyNumber=0, likeNumber=61, createdTime=2020-09-17, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c95e19626e25, moduleTitle=Int J Clin Oncol：卡铂或西妥昔单抗加放疗对不能接受顺铂治疗的局部晚期头颈部癌症患者的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c95e19626e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650789, encodeId=a81e1650e890d, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Eur J Cancer：局部晚期头颈鳞状细胞癌老年患者强化放疗激活NBTXR3的I期剂量递增研究, objectType=article, longId=207381, objectId=313020e38117, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=313020e38117, replyNumber=0, likeNumber=47, createdTime=2021-03-18, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=313020e38117, moduleTitle=Eur J Cancer：局部晚期头颈鳞状细胞癌老年患者强化放疗激活NBTXR3的I期剂量递增研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=313020e38117)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650795, encodeId=5bca1650e953b, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Int J Radiat Oncol Biol Phys：放疗不遵守指南会降低局部晚期胰腺癌患者存活率！, objectType=article, longId=209330, objectId=3d9c2093300c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d9c2093300c, replyNumber=0, likeNumber=58, createdTime=2021-08-10, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d9c2093300c, moduleTitle=Int J Radiat Oncol Biol Phys：放疗不遵守指南会降低局部晚期胰腺癌患者存活率！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d9c2093300c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650798, encodeId=5d2c1650e98b7, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=J Clin Oncol：震惊！局部晚期可切除的食管癌患者从术前放化疗中的生存获益可至少持续10年！, objectType=article, longId=210515, objectId=4d42210515e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d42210515e4, replyNumber=0, likeNumber=73, createdTime=2021-06-19, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d42210515e4, moduleTitle=J Clin Oncol：震惊！局部晚期可切除的食管癌患者从术前放化疗中的生存获益可至少持续10年！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d42210515e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650781, encodeId=3d451650e817a, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, objectType=article, longId=201182, objectId=099320118291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=099320118291, replyNumber=0, likeNumber=52, createdTime=2021-03-02, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=099320118291, moduleTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=099320118291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650776, encodeId=2f2b1650e76ee, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Lancet oncol：Debio 1143治疗局部晚期头颈部鳞状细胞癌, objectType=article, longId=198710, objectId=a8d7198e10e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8d7198e10e3, replyNumber=0, likeNumber=74, createdTime=2020-10-01, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8d7198e10e3, moduleTitle=Lancet oncol：Debio 1143治疗局部晚期头颈部鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8d7198e10e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650775, encodeId=651f1650e7501, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Cancer：二甲双胍联合顺铂和放疗治疗局部晚期头颈部鳞状细胞癌的效果, objectType=article, longId=198497, objectId=df1419849e05, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df1419849e05, replyNumber=0, likeNumber=62, createdTime=2020-09-13, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df1419849e05, moduleTitle=Cancer：二甲双胍联合顺铂和放疗治疗局部晚期头颈部鳞状细胞癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df1419849e05)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650790, encodeId=b7811650e90af, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Eur J Cancer：可准确评估局部晚期乳腺癌患者NAC后的完全缓解的深度学习模型！, objectType=article, longId=207604, objectId=767720e604bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=767720e604bc, replyNumber=0, likeNumber=56, createdTime=2021-04-28, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=767720e604bc, moduleTitle=Eur J Cancer：可准确评估局部晚期乳腺癌患者NAC后的完全缓解的深度学习模型！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=767720e604bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650773, encodeId=c8211650e73b0, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Cancer：尼莫妥珠单抗+顺铂化放疗vs单纯顺铂化放疗治疗局部晚期头颈癌的效果, objectType=article, longId=196262, objectId=49081962624e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49081962624e, replyNumber=0, likeNumber=88, createdTime=2020-08-22, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49081962624e, moduleTitle=Cancer：尼莫妥珠单抗+顺铂化放疗vs单纯顺铂化放疗治疗局部晚期头颈癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49081962624e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650788, encodeId=545f1650e88c7, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=欧盟批准Tukysa，用于治疗HER2阳性的局部晚期或转移性乳腺癌, objectType=article, longId=207278, objectId=c7b720e278ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7b720e278ca, replyNumber=0, likeNumber=85, createdTime=2021-06-24, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7b720e278ca, moduleTitle=欧盟批准Tukysa，用于治疗HER2阳性的局部晚期或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7b720e278ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650785, encodeId=7ff31650e8519, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=患者招募：Pamrevlumab或安慰剂联合吉西他滨/白蛋白紫杉醇（G/N）作为新辅助治疗用于局部晚期不可切除胰腺癌：一项III期、随机、双盲研究, objectType=article, longId=204949, objectId=3e49204949d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e49204949d8, replyNumber=0, likeNumber=86, createdTime=2021-05-25, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e49204949d8, moduleTitle=患者招募：Pamrevlumab或安慰剂联合吉西他滨/白蛋白紫杉醇（G/N）作为新辅助治疗用于局部晚期不可切除胰腺癌：一项III期、随机、双盲研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e49204949d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650778, encodeId=66871650e78b6, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Eur Urol：局部晚期和转移性尿道癌中成纤维细胞生长因子受体3的变异状态与对铂化疗敏感性的差异相关, objectType=article, longId=199985, objectId=72b119998516, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72b119998516, replyNumber=0, likeNumber=77, createdTime=2020-09-28, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72b119998516, moduleTitle=Eur Urol：局部晚期和转移性尿道癌中成纤维细胞生长因子受体3的变异状态与对铂化疗敏感性的差异相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72b119998516)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650769, encodeId=f0fa1650e69b4, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Lancet Gastroen Hepatol：Nab紫杉醇联合吉西他滨一线治疗局部晚期胰腺癌, objectType=article, longId=186330, objectId=ccce18633096, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccce18633096, replyNumber=0, likeNumber=58, createdTime=2020-05-09, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccce18633096, moduleTitle=Lancet Gastroen Hepatol：Nab紫杉醇联合吉西他滨一线治疗局部晚期胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccce18633096)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650770, encodeId=81aa1650e7097, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Lancet Oncol：Cemiplimab治疗局部晚期皮肤鳞状细胞癌, objectType=article, longId=186331, objectId=e0e618633192, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0e618633192, replyNumber=0, likeNumber=88, createdTime=2020-01-22, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0e618633192, moduleTitle=Lancet Oncol：Cemiplimab治疗局部晚期皮肤鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0e618633192)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650779, encodeId=20d61650e790e, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Nat Commun：哪些局部晚期直肠癌患者才能从化疗中获益？, objectType=article, longId=200011, objectId=aeac200011f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeac200011f6, replyNumber=0, likeNumber=76, createdTime=2021-01-19, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeac200011f6, moduleTitle=Nat Commun：哪些局部晚期直肠癌患者才能从化疗中获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeac200011f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650777, encodeId=b2411650e77c1, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=JTO：信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状NSCLC一线治疗的有效性和安全性(ORIENT-11), objectType=article, longId=199903, objectId=f051199903bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f051199903bb, replyNumber=0, likeNumber=61, createdTime=2020-09-05, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f051199903bb, moduleTitle=JTO：信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状NSCLC一线治疗的有效性和安全性(ORIENT-11), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f051199903bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

局部晚期

2020-05-29

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Ann Surg：联合血管切除术治疗局部晚期肝门部胆管癌

2021-03-24

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

ASCO GI 2021：帕博利珠单抗+放化疗全程新辅助治疗局部晚期直肠癌，未能改善NAR评分（NRG-GI002研究）

2021-05-29

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！

2021-07-16

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Lancet Oncol：中山大学肿瘤医院郭翔教授团队通过3期试验证实第三代铂类药物洛铂可有效治疗局部晚期鼻咽癌！

2021-10-17

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Int J Clin Oncol：卡铂或西妥昔单抗加放疗对不能接受顺铂治疗的局部晚期头颈部癌症患者的安全性和有效性

2020-09-17

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Eur J Cancer：局部晚期头颈鳞状细胞癌老年患者强化放疗激活NBTXR3的I期剂量递增研究

2021-03-18

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Int J Radiat Oncol Biol Phys：放疗不遵守指南会降低局部晚期胰腺癌患者存活率！

2021-08-10

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

J Clin Oncol：震惊！局部晚期可切除的食管癌患者从术前放化疗中的生存获益可至少持续10年！

2021-06-19

仁者大医 (审核中...)

前往app查看评论内容

#局部晚期#

Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率

2021-03-02

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Lancet oncol：Debio 1143治疗局部晚期头颈部鳞状细胞癌

2020-10-01

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Cancer：二甲双胍联合顺铂和放疗治疗局部晚期头颈部鳞状细胞癌的效果

2020-09-13

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Eur J Cancer：可准确评估局部晚期乳腺癌患者NAC后的完全缓解的深度学习模型！

2021-04-28

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Cancer：尼莫妥珠单抗+顺铂化放疗vs单纯顺铂化放疗治疗局部晚期头颈癌的效果

2020-08-22

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

欧盟批准Tukysa，用于治疗HER2阳性的局部晚期或转移性乳腺癌

2021-06-24

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

患者招募：Pamrevlumab或安慰剂联合吉西他滨/白蛋白紫杉醇（G/N）作为新辅助治疗用于局部晚期不可切除胰腺癌：一项III期、随机、双盲研究

2021-05-25

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Eur Urol：局部晚期和转移性尿道癌中成纤维细胞生长因子受体3的变异状态与对铂化疗敏感性的差异相关

2020-09-28

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Lancet Gastroen Hepatol：Nab紫杉醇联合吉西他滨一线治疗局部晚期胰腺癌

2020-05-09

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Lancet Oncol：Cemiplimab治疗局部晚期皮肤鳞状细胞癌

2020-01-22

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Nat Commun：哪些局部晚期直肠癌患者才能从化疗中获益？

2021-01-19

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

JTO：信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状NSCLC一线治疗的有效性和安全性(ORIENT-11)

2020-09-05

科室
- - 订阅+
  - 更多科室
工具
服务